Idiopathic Pulmonary Fibrosis is scarring in the lungs from unknown causes such as disease, injury or genetics. The condition prevents the alveoli in the lungs from effectively transferring oxygen to the bloodstream.
Pleural effusion describes a condition in which fluid surrounding the lungs in the pleural space reduces the lung's capacity for expansion. This condition can be complicated by infection of the fluid or scarring that traps the fluid in the pleural space.
Lung Therapeutics is currently focused on developing LTI-03, a pharmaceutical treatment for Idiopathic Pulmonary Fibrosis, which shows promise for treating fibrosis and restoring lung function. Another lung disease indication, loculated pleural effusion, is currently being targeted with a clinical program for the compound LTI-01 beginning in 2016. For each of our programs, Lung Therapeutics seeks orphan drug status to expedite development of market-ready products
Founder and Chief Scientific Officer, Dr. Steven Idell, M.D., Ph.D., has been leading the way in lung injury and disease, with more than 25 years of funded research. Dr. Idell has obtained more than $27 million in grant support from the NIH, The American Heart Association, The American Lung Association and various foundations. Dr. Idell has published more than 150 research articles related to lung injury and disease.
Lung disease includes a range of illnesses such as asthma, bronchitis, chronic obstructive pulmonary disease (COPD), pneumonia, lung cancer, cystic fibrosis, and other complications related to these illnesses. Pneumonia alone affects more than 150 million people globally each year.1 Dangerous complications of pneumonia occur in some cases, including PE, CPE, empyema and loculation. Other lung diseases such as Idiopathic Pulmonary Fibrosis create life-threatening conditions that can be unresponsive to therapy and may require thoracic surgery.
However, the relatively low frequency of these conditions means they are often overlooked by drug companies as new clinical targets. Physicians need better tools to treat these rare and serious lung conditions. For the patients and families affected by such orphan diseases, new treatments cannot come soon enough.
1 Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H, WHO Child Health Epidemiology Reference Group. (2004). Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ. 82(12):895-903.
Lung Therapeutics has multiple drugs in clinical or pre-clinical development. Results to date show promise as non-surgical treatment options for these and fibrotic diseases. Lung Therapeutics has received orphan drug designation from both the FDA and the European Commission for LTI-01 in the treatment of empyema. For patients and physicians whose previous clinical options were limited, invasive and costly, Lung Therapeutics is giving them some breathing room.Discover Our Therapies